सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

**File No. CT/25/000023**

To
M/s GSK Pharma India Private Limited.,
01, Battery House Bhulabhai Desai Road,
Mumbai, Maharashtra (India) – 400026.

Sir,

With reference to your application no. GCT/CT04/FF/2025/48116 dated 04-Mar-2025, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer" Protocol no.: 219606 amendment 4, dated 22-AUG-2024 with a total of up-to 40 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, specifically::-

**(i) Human biological samples i.e. Whole blood, Plasma, Serum, Tissue sample (pre/screening biopsy) and Tissue sample (surgery biopsy) related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO. Further, ICMR/DHR permission shall be obtained for export of optional biological samples as per DGFT notification number 72/2023 dated 11.03.2024.**

**(ii)** Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

**(iii)** Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

**(iv)** In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

**(v)** The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

**(vi)** Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

**(vii)** Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

**(viii)** Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on

quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

**(ix)** Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

**(x)** In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

**(xi)** Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

**(xii)** In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

**(xiii)** In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

**(xiv)** The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

**(xv)** Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

**(xvi)** The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

**(xvii)** The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

**(xviii)** The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

**(xix)** Merely granting permission to conduct the **clinical trial** with the Investigational Drug Product does not convey or imply that, based on the **clinical trial study data** generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

**(xx)** The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.07.11 12:02:52 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

**FORM CT-06**

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG**

**1.** The Central Licensing Authority hereby permits **M/s GSK Pharma India Private Limited, 01, Battery House, Bhulabhai Desai Road, Mumbai, Maharashtra, (India) - 400026** to conduct clinical trial of the new drug or investigational new drug as per **Protocol no.: 219606 amendment 4, dated 22-AUG-2024** in the below mentioned clinical trial sites [As per Annexure].-

**2**. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

**3**. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.07.11 12:03:10 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

**Note:** The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

**Annexure:**

Details of new drug or investigational new drug:

| | |
|---|---|
| **Names of the new drug or investigational new drug** | Dostarlimab |
| **Therapeutic class:** | Anticancer |
| **Dosage form:** | Solution for infusion |
| **Composition:** | Polysorbate 80 =2.0000 mg/vial Any Other Pharmacopia, J.P.,Ph. Eur Inactive<br>Water for Injection =0.0000 qsto 10 mL U.S.P.,J.P.,Ph.Eur Inactive<br>Citric Acid, Monohydrate=4.8000 mg/vial U.S.P.,J.P.,Ph.Eur Inactive<br>Sodium Citrate, Dihydrate=66.8000 mg/vial U.S.P.,J.P.,Ph.Eur Inactive<br>L-Arginine, Hydrochloride=210.6600 mg/vial U.S.P.,J.P.,Ph.Eur Inactive<br>Sodium Chloride =18.1100 mg/vial U.S.P.,J.P.,Ph.Eur Inactive<br>Dostarlimab =500.0000 mg/vial In House Specification Active |
| **Indications:** | Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |

**Annexure:**

Details of clinical trial site:

| S. No. | Name and address of clinical trial site | Ethics Committee Details | Name of Investigator |
|---|---|---|---|
| **1.** | TATA Memorial Hospital, Main Building, 3rd floor, Dr. Ernest Borges Road, Parel, Mumbai Maharashtra - 400012 | Tata Memorial Centre-Institutional Ethics Committee-I Tata Memorial Centre-Institutional Ethics Committee-II Dr Ernest Borges Road, Parel, Mumbai 400012<br><br>ECR/170/Inst/MH/2013/RR-22<br>ECR/414/Inst/MH/2013/RR-24 | Dr Anant Ramaswamy |
| **2.** | Basvatarakam Indo-American Cancer Hospital & Research Institute, Road No. 14, Banjara Hills Hyderabad Andhra Pradesh - 500034 | Institutional ethics Committee, Basavatarakam Indo Merican Cancer Hospital & research Institute, Road No 10, Banjara hills, Hyderabad - 500034, Telangana, India<br><br>ECR/7/Inst/AP/2013/RR-20 | Dr MVT Krishna Mohan |
| **3.** | Chittaranjan National cancer institute, Institutional ethics committee for clinical research Chittarajan National cancer Institute, 37 SP Mukherjee Raod Kolkata West Bengal -700026 | Institutional Ethics Committee Chittaranjan National Cancer Institute 37, S.P Mukherjee Road, Kolkata-700026. West Bengal, India<br><br>ECR/241/Inst/WB/2013/RR-20 | Dr Kalyan Kusum Mukherjee |
| **4.** | Medanta Institute of Education and Research Regulatory, Medanta Institute of Education and Research Regulatory office, IInd Floor, Opposite Medical Library, Training Block, Medanta- The Medicity, Sector-38, Gurgaon Haryana -122001 | Medanta Institutional Ethics Committee (MIEC)10th Floor, A-wing (POCU), Medanta The Medicity, Sector-38, Gurgaon, Haryana -122001<br><br>ECR/282/Inst/HR/2013/RR-20 | Dr Ashok Kumar Vaid |
| **5.** | Department of Pharmacology, Department of Pharmacology, JIPMER Puducherry Tamil Nadu - 605006 | Institutional Ethics Committee Intervention Studies JIPMER, Dhanvantri Nagar Pondicherry, Pondicherry-605006, India<br><br>ECR/342/Inst/PY/2013/RR-19 | Dr Smita Kayal |
| **6.** | Inamdar Multispeciality Hospital, Ethics Committee, Inamdar Multispeciality Hospital, Hospital Building, S. No. 15, Fatima Nagar Pune Maharashtra - 411040 | Ethics Committee Inamdar Multispeciality Hospital CIMETs Inamdar Mutispeciality Hospital. Hospital Building S.No .15, Fatima Nagar ,Wanawadi. Pune Pune Maharashtra -411040 India<br><br>ECR/354/Inst/MH/2013/RR-20 | Dr Minish Mahendra Jain |
| **7.** | Fortis Hospital, Fortis Hospital Ethics Committee, 154/9, Bannerghatta Road, Opp. IIM-B, Bangalore Karnataka - 560076 | Institutional Ethics Committee Fortis Hospitals 154/9, Bannerghatta Road, Opp. IIM-B, Bengaluru-560076<br><br>ECR/378/Inst/KA/2013/RR-24 | Dr Niti Raizada |

| | | | |
|---|---|---|---|
| **8.** | Manavata Clinical Research Institute Ethics Committee (MCRI EC), Manavata Clinical Research Institute Ethics Committee (MCRI EC) situatedat Curie Manavata Cancer Centre, Opp. Mahamarg Bus Stand, Mumbai Naka, Nashik Maharashtra - 422004 | Manavata Clinical Institute Ethics Committee Behind Shivang Auto, Mumbai Naka Nashik-422004<br><br>ECR/500/Inst/MH/2013/RR-20 | Dr Mukesh Chaudhari |
| **9.** | All India Institute of Medical Sciences , Ethics Committee All India Institute of Medical Sciences situated at Village Sijua, Patrapada, PO Dumduma, Bhubaneshwar Orissa - 751019 | INSTITUTIONAL ETHICS COMMITTEE, AIIMS Bhubaneshwar All India Institute of Medical Sciences, BBSR AIIMS Bhubhaneswar Sijua P/O Patrapada Bhubaneswar Khordha Orissa-751019 India<br><br>ECR/534/Inst/OD/2014/RR-20 | Dr Sourav Kumar Mishra |
| **10.** | Institutional Fortis Hospital, Institutional Ethics Committee, Fortis Hospital situated at Mundian kurd, Ludhiana Punjab - 141015 | Institutional Ethics Committee Fortis Hospital Ludhiana Mundian Kalan, Chandigarh Road, Ludhiana, Punjab 141015<br><br>ECR/746/Inst/PB/2015/RR-22 | Dr Davinder Paul |
| **11.** | Rukmani Birla Hospital-A Unit of CMRI, Near Triveni Flyover Gopalpura Bypass Road Gopalpura Rajasthan - 302018 | Ethics Committee SMS Medical College and Hospital SMS Medical College and Hospital J.L.N Marg Jaipur-302004, Rajasthan, India<br><br>ECR/26/Inst/RJ/2013/RR-24 | Dr Sandeep Kumar Jasuja |
| **12.** | Mumbai Oncocare and Research Centre, 1st Floor, SS house, Nehru road, Vile Parle, Vile Parle east Mumbai Maharashtra - 400057 | Mumbai Oncocare Centre Institutional Ethics Committee Cellcure Cancer Centre Private Limited1 To 4 floor -1st shreepati Arcade, August kranti Marg Nana Chowk Mumbai 400036<br><br>ECR/1277/Inst/MH/2019/RR-24 | Dr Ashish Anand Joshi |
| **13.** | Meadowlark Healthcare, Meadowlark Hospital Pune Wing C,17 48, Bhairobanala Road, Next to fatima nagar Pune Maharashtra - 411001 | IEC Dr. Mhaske Hospital and Research Centre Dr. Mhaske Hospital and Research Centre Jiyaji Mention Building, Near UCO Bank Next to Old Post Office, Gadital, Gadital Pune Pune Maharashtra -411028 India | Dr Tushar Vishwasrao Patil |

| | | | |
|---|---|---|---|
| | | ECR/1524/Inst/MH/2021 | |

**********